Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Puma Plummets On Another Neratinib NDA Delay

This article was originally published in Scrip

Executive Summary

Puma Biotechnology Inc. fell 21.1% to close at $27.92 per share on March 29 after it revealed a second major delay for the company's new drug application (NDA) submission to the US FDA for neratinib as an extended adjuvant treatment for early-stage HER2-positive breast cancer.

You may also be interested in...



Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine

"Basket trial" design allowed Puma to identify certain cohorts for further study, but also missed in areas where neratinib was expected to work.

Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol

The latest drug development news and highlights from our FDA Performance Tracker

First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC

Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.

Topics

UsernamePublicRestriction

Register

SC064848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel